News Sentiment

LONA sentiment intelligence

LeonaBio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 23 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.60 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 15

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+8.2% over one week, +15.0% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

LeonaBio, Inc.(NasdaqCM: LONA) added to Russell 3000E Index

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 8.2% Price confirming higher
Trend fit Trend active 15.0% over four weeks
Fair value -26.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 4
Neutral 16
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 15
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 5
simplywall.st 2
TradingView 2
marketscreener.com 1
MarketBeat 1
Simply Wall St 1
Zacks Investment Research 1

Event Lens

What the news is about

Classified themes
Market update 11
Earnings 9
Analyst action 1
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-23 of 23
Stock Titan Direct company coverage

Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63

LeonaBio, Inc. Director Callori Fred was granted 56,000 stock options with an exercise price of $9.63 per share, expiring on May 4, 2036. These options will vest monthly in equal installments over 36 months, provided the director continues to serve under the company's 2026 Equity

Tone
Neutral 50/100
Event
Market update
Published
08 May 2026 00:39
Source
Stock Titan
Stock Titan Direct company coverage

LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials

LeonaBio (NASDAQ: LONA) reported a widened net loss of $32.9 million for Q1 2026, primarily due to increased R&D expenses for its Phase 3 ELAINE-3 trial for metastatic breast cancer and higher general and administrative costs. Despite the loss, the company is advancing its late-s

Tone
Negative 39/100
Event
Market update
Published
07 May 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA)

LeonaBio, Inc. director John M. Fluke Jr. was granted options to purchase 28,000 shares of common stock. The stock option has an exercise price of $9.54 per share and an expiration date of April 8, 2036. This award, given as compensation, vests in equal monthly installments over

Tone
Neutral 50/100
Event
Market update
Published
14 Apr 2026 06:10
Source
Stock Titan
Stock Titan Direct company coverage

LeonaBio (LONA) grants CMO 350,000 options at $9.54

LeonaBio, Inc. (LONA) has granted its Chief Medical Officer, Javier San Martin, 350,000 stock options at an exercise price of $9.54 per share. These options, which expire on April 8, 2036, will vest in equal monthly installments over 48 months, contingent on San Martin's continue

Tone
Neutral 50/100
Event
Market update
Published
13 Apr 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

28,000-share stock option grant to LeonaBio (LONA) director

LeonaBio, Inc. director Michael A. Panzara received a compensatory stock option grant for 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. These option shares will vest in equal monthly installments over 24 months,

Tone
Neutral 50/100
Event
Market update
Published
13 Apr 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

28,000 stock options granted to LeonaBio (LONA) director Kosacz

LeonaBio, Inc. director Barbara Kosacz was granted 28,000 stock options with an exercise price of $9.54 per share, expiring on April 8, 2036. The options will vest in equal monthly installments over 24 months, contingent on her continued service as a Service Provider. This is a r

Tone
Neutral 50/100
Event
Market update
Published
13 Apr 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug

LeonaBio (NASDAQ: LONA) reported its full-year 2025 financial results, showing an increase in cash and investments to $88.3 million, largely due to a $90 million private placement. The company's net loss widened to $105.6 million. This financial boost secures funding for its Phas

Tone
Positive 67/100
Event
Earnings
Published
26 Mar 2026 23:38
Source
Stock Titan
MarketBeat Direct company coverage

Athira Pharma (LONA) Stock Price, News & Analysis $LONA

Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for neurodegenerative and cognitive disorders. As of May 22, 2026, its stock closed at $10.33, with an average price target of $10.00 from analysts, indicat

Tone
Neutral 50/100
Event
Analyst action
Published
13 Feb 2026 11:08
Source
MarketBeat
Simply Wall St Direct company coverage

LeonaBio (Nasdaq:LONA) - Stock Analysis

LeonaBio (Nasdaq:LONA) is a clinical-stage biopharmaceutical company focused on neurodegeneration. The company has a market cap of US$52.6m, with its share price being highly volatile over the past 3 months and shareholders experiencing substantial dilution. LeonaBio currently ha

Tone
Negative 29/100
Event
Market update
Published
03 Feb 2026 00:52
Source
Simply Wall St
Stock Titan Direct company coverage

ATHA Stock Price, News & Analysis

Athira Pharma (ATHA) has rebranded to LeonaBio, Inc. with a new ticker symbol "LONA," focusing on developing novel therapeutics for treatment-resistant metastatic breast cancer and ALS. The company's lead drug candidates are lasofoxifene, currently in a Phase 3 trial for breast c

Tone
Positive 63/100
Event
Market update
Published
09 Jan 2026 15:40
Source
Stock Titan
GlobeNewswire Direct company coverage

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

Athira Pharma has officially changed its name to LeonaBio, Inc. and will trade under the new ticker symbol "LONA" on The Nasdaq Capital Market starting January 12, 2026. This rebranding follows the acquisition of rights to develop lasofoxifene, a Phase 3 asset for metastatic brea

Tone
Positive 76/100
Event
Deals and strategy
Published
09 Jan 2026 07:00
Source
GlobeNewswire